Gregory Kinney
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 65 | 2026 | 919 | 6.580 |
Why?
| | Smoking | 34 | 2026 | 1470 | 2.130 |
Why?
| | Coronary Artery Disease | 28 | 2025 | 747 | 1.790 |
Why?
| | Tomography, X-Ray Computed | 44 | 2026 | 2767 | 1.700 |
Why?
| | Smokers | 18 | 2025 | 136 | 1.650 |
Why?
| | Pulmonary Emphysema | 14 | 2025 | 277 | 1.480 |
Why?
| | Diabetes Mellitus, Type 1 | 38 | 2025 | 3918 | 1.450 |
Why?
| | Cannabis | 10 | 2025 | 509 | 1.360 |
Why?
| | Forced Expiratory Volume | 28 | 2026 | 450 | 1.280 |
Why?
| | Bronchiectasis | 7 | 2023 | 112 | 0.950 |
Why?
| | Calcinosis | 17 | 2015 | 234 | 0.930 |
Why?
| | Spirometry | 18 | 2026 | 233 | 0.890 |
Why?
| | Lung | 24 | 2026 | 4101 | 0.860 |
Why?
| | Dronabinol | 4 | 2024 | 249 | 0.820 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 543 | 0.800 |
Why?
| | Hyperlipidemias | 2 | 2023 | 120 | 0.780 |
Why?
| | Disease Progression | 29 | 2026 | 2857 | 0.770 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 209 | 0.750 |
Why?
| | Middle Aged | 100 | 2026 | 36126 | 0.750 |
Why?
| | Marijuana Smoking | 3 | 2022 | 249 | 0.740 |
Why?
| | Cannabinoids | 5 | 2024 | 184 | 0.730 |
Why?
| | Cardiovascular System | 1 | 2023 | 138 | 0.720 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 2183 | 0.660 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2026 | 2578 | 0.650 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 264 | 0.640 |
Why?
| | Female | 121 | 2026 | 78636 | 0.620 |
Why?
| | Volatilization | 1 | 2019 | 45 | 0.610 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 62 | 0.600 |
Why?
| | Risk Factors | 41 | 2025 | 10857 | 0.600 |
Why?
| | Male | 111 | 2026 | 72664 | 0.600 |
Why?
| | Humans | 147 | 2026 | 145140 | 0.590 |
Why?
| | Aged | 55 | 2026 | 26096 | 0.580 |
Why?
| | Coronary Vessels | 8 | 2025 | 246 | 0.560 |
Why?
| | Cohort Studies | 34 | 2026 | 5988 | 0.550 |
Why?
| | Prenatal Exposure Delayed Effects | 4 | 2026 | 650 | 0.540 |
Why?
| | Coronary Disease | 8 | 2025 | 381 | 0.530 |
Why?
| | Marijuana Abuse | 1 | 2019 | 211 | 0.490 |
Why?
| | Genetic Predisposition to Disease | 12 | 2026 | 2351 | 0.480 |
Why?
| | Air Pollution | 1 | 2019 | 312 | 0.470 |
Why?
| | Genome-Wide Association Study | 11 | 2026 | 1376 | 0.470 |
Why?
| | Vascular Calcification | 5 | 2019 | 110 | 0.470 |
Why?
| | Prospective Studies | 30 | 2025 | 8035 | 0.460 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 24 | 0.450 |
Why?
| | Risk Assessment | 9 | 2024 | 3740 | 0.450 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1174 | 0.450 |
Why?
| | Lung Diseases, Interstitial | 4 | 2025 | 659 | 0.440 |
Why?
| | Cigarette Smoking | 3 | 2025 | 101 | 0.440 |
Why?
| | Adult | 58 | 2026 | 40665 | 0.410 |
Why?
| | Quantitative Trait Loci | 2 | 2026 | 375 | 0.410 |
Why?
| | Depression | 5 | 2025 | 1537 | 0.380 |
Why?
| | Vital Capacity | 8 | 2025 | 292 | 0.380 |
Why?
| | Pulmonary Artery | 5 | 2024 | 1126 | 0.350 |
Why?
| | Cannabidiol | 2 | 2024 | 142 | 0.340 |
Why?
| | Atherosclerosis | 4 | 2023 | 409 | 0.330 |
Why?
| | Longitudinal Studies | 10 | 2024 | 2949 | 0.330 |
Why?
| | Biomarkers | 13 | 2025 | 4282 | 0.330 |
Why?
| | Airway Obstruction | 2 | 2024 | 153 | 0.330 |
Why?
| | Emphysema | 2 | 2023 | 100 | 0.320 |
Why?
| | Walk Test | 3 | 2026 | 81 | 0.310 |
Why?
| | Exercise Tolerance | 4 | 2026 | 283 | 0.310 |
Why?
| | Prevalence | 13 | 2025 | 2855 | 0.310 |
Why?
| | Polymorphism, Single Nucleotide | 8 | 2026 | 2136 | 0.300 |
Why?
| | Cross-Sectional Studies | 17 | 2026 | 5886 | 0.290 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 18 | 0.280 |
Why?
| | Lipoproteins | 3 | 2016 | 166 | 0.280 |
Why?
| | Marijuana Use | 3 | 2024 | 221 | 0.280 |
Why?
| | Albuminuria | 4 | 2016 | 189 | 0.280 |
Why?
| | Case-Control Studies | 15 | 2025 | 3616 | 0.280 |
Why?
| | Proportional Hazards Models | 7 | 2025 | 1325 | 0.270 |
Why?
| | Calcium | 7 | 2018 | 1189 | 0.270 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2928 | 0.270 |
Why?
| | Metformin | 2 | 2021 | 327 | 0.260 |
Why?
| | Bronchi | 3 | 2022 | 263 | 0.260 |
Why?
| | Blood Glucose | 7 | 2026 | 2335 | 0.250 |
Why?
| | Bronchodilator Agents | 2 | 2026 | 187 | 0.250 |
Why?
| | Predictive Value of Tests | 11 | 2019 | 2115 | 0.250 |
Why?
| | Anxiety | 3 | 2025 | 1117 | 0.240 |
Why?
| | Uteroglobin | 1 | 2026 | 30 | 0.240 |
Why?
| | Young Adult | 15 | 2023 | 14176 | 0.240 |
Why?
| | Body Mass Index | 11 | 2024 | 2437 | 0.240 |
Why?
| | Follow-Up Studies | 12 | 2026 | 5411 | 0.230 |
Why?
| | Logistic Models | 13 | 2025 | 2133 | 0.230 |
Why?
| | United States | 13 | 2026 | 16065 | 0.230 |
Why?
| | Monitoring, Intraoperative | 3 | 2010 | 66 | 0.230 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 571 | 0.220 |
Why?
| | Aged, 80 and over | 11 | 2025 | 8318 | 0.220 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 252 | 0.220 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 13 | 0.220 |
Why?
| | Precision Medicine | 2 | 2026 | 459 | 0.220 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 78 | 0.220 |
Why?
| | Lumbar Vertebrae | 3 | 2020 | 252 | 0.220 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 222 | 0.220 |
Why?
| | Cause of Death | 2 | 2018 | 470 | 0.220 |
Why?
| | Antidepressive Agents | 3 | 2019 | 239 | 0.220 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 61 | 0.210 |
Why?
| | Adrenal Insufficiency | 1 | 2025 | 31 | 0.210 |
Why?
| | Self Administration | 1 | 2025 | 122 | 0.210 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 229 | 0.210 |
Why?
| | Quality of Life | 4 | 2021 | 3194 | 0.210 |
Why?
| | RNA Splicing | 1 | 2026 | 284 | 0.210 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 130 | 0.210 |
Why?
| | Birth Weight | 2 | 2024 | 513 | 0.210 |
Why?
| | Renal Insufficiency | 2 | 2016 | 172 | 0.210 |
Why?
| | Vaping | 1 | 2025 | 69 | 0.200 |
Why?
| | Symptom Flare Up | 2 | 2021 | 37 | 0.200 |
Why?
| | C-Peptide | 1 | 2025 | 190 | 0.200 |
Why?
| | Dyspnea | 5 | 2024 | 250 | 0.190 |
Why?
| | Polysomnography | 1 | 2024 | 239 | 0.190 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 71 | 0.190 |
Why?
| | Hydrocortisone | 1 | 2025 | 298 | 0.190 |
Why?
| | Fibrinogen | 3 | 2014 | 180 | 0.190 |
Why?
| | Adiponectin | 4 | 2016 | 241 | 0.190 |
Why?
| | Population Health | 1 | 2023 | 44 | 0.180 |
Why?
| | Phenotype | 6 | 2025 | 3138 | 0.180 |
Why?
| | Multimorbidity | 1 | 2023 | 64 | 0.180 |
Why?
| | Limit of Detection | 2 | 2019 | 92 | 0.180 |
Why?
| | Organ Size | 5 | 2025 | 459 | 0.180 |
Why?
| | Propofol | 2 | 2021 | 85 | 0.180 |
Why?
| | Umbilical Cord | 2 | 2021 | 92 | 0.180 |
Why?
| | Gene Expression Profiling | 2 | 2026 | 1763 | 0.180 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.180 |
Why?
| | Cystatin C | 3 | 2011 | 66 | 0.170 |
Why?
| | Cholesterol | 4 | 2011 | 406 | 0.170 |
Why?
| | Models, Genetic | 1 | 2024 | 523 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 101 | 0.170 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 73 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 140 | 0.170 |
Why?
| | Walking | 1 | 2026 | 542 | 0.170 |
Why?
| | Protective Agents | 1 | 2021 | 42 | 0.170 |
Why?
| | Sarcopenia | 1 | 2022 | 91 | 0.170 |
Why?
| | Artificial Intelligence | 2 | 2023 | 381 | 0.170 |
Why?
| | Hand Strength | 2 | 2022 | 144 | 0.170 |
Why?
| | Self Report | 3 | 2021 | 867 | 0.160 |
Why?
| | Hallucinogens | 1 | 2023 | 111 | 0.160 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 307 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2025 | 531 | 0.160 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 115 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 512 | 0.160 |
Why?
| | C-Reactive Protein | 2 | 2014 | 422 | 0.160 |
Why?
| | Foraminotomy | 1 | 2020 | 1 | 0.160 |
Why?
| | Muscular Atrophy | 1 | 2021 | 87 | 0.160 |
Why?
| | Paresthesia | 1 | 2020 | 14 | 0.160 |
Why?
| | Hepatitis C | 1 | 2023 | 256 | 0.150 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.150 |
Why?
| | Osteoporosis | 1 | 2022 | 237 | 0.150 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 7 | 0.150 |
Why?
| | Lumbosacral Region | 1 | 2020 | 59 | 0.150 |
Why?
| | Foam Cells | 1 | 2019 | 17 | 0.150 |
Why?
| | Genetic Markers | 2 | 2019 | 333 | 0.150 |
Why?
| | Hyperostosis | 1 | 2019 | 5 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2025 | 866 | 0.150 |
Why?
| | Delirium | 1 | 2021 | 105 | 0.150 |
Why?
| | Calibration | 1 | 2019 | 151 | 0.150 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 319 | 0.150 |
Why?
| | Regression Analysis | 6 | 2022 | 998 | 0.150 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 174 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2019 | 82 | 0.150 |
Why?
| | Multifactorial Inheritance | 3 | 2025 | 190 | 0.140 |
Why?
| | Surface Properties | 1 | 2019 | 386 | 0.140 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 48 | 0.140 |
Why?
| | Diabetes Complications | 2 | 2010 | 224 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1185 | 0.140 |
Why?
| | Heart Ventricles | 2 | 2020 | 754 | 0.140 |
Why?
| | Adipose Tissue | 2 | 2017 | 644 | 0.140 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 614 | 0.130 |
Why?
| | Insulin Resistance | 4 | 2017 | 1244 | 0.130 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 199 | 0.130 |
Why?
| | Drug Overdose | 1 | 2022 | 374 | 0.130 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 290 | 0.130 |
Why?
| | Linear Models | 6 | 2019 | 844 | 0.130 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2025 | 690 | 0.130 |
Why?
| | Urine | 1 | 2017 | 64 | 0.130 |
Why?
| | Population Surveillance | 1 | 2021 | 484 | 0.130 |
Why?
| | Vascular Remodeling | 1 | 2019 | 209 | 0.130 |
Why?
| | Sleep | 1 | 2024 | 887 | 0.130 |
Why?
| | Environmental Monitoring | 1 | 2019 | 346 | 0.130 |
Why?
| | Gene Expression Regulation | 1 | 2026 | 2588 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1806 | 0.130 |
Why?
| | Evoked Potentials, Somatosensory | 3 | 2015 | 39 | 0.120 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 41 | 0.120 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 259 | 0.120 |
Why?
| | Lung Diseases | 1 | 2023 | 780 | 0.120 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 16 | 0.120 |
Why?
| | HIV Infections | 2 | 2023 | 3186 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 309 | 0.120 |
Why?
| | Blood Pressure | 5 | 2023 | 1778 | 0.120 |
Why?
| | Pregnancy | 6 | 2026 | 7182 | 0.120 |
Why?
| | Obesity | 4 | 2022 | 3097 | 0.120 |
Why?
| | Plasma | 1 | 2017 | 223 | 0.120 |
Why?
| | Aortography | 1 | 2015 | 52 | 0.110 |
Why?
| | Comorbidity | 5 | 2021 | 1657 | 0.110 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1546 | 0.110 |
Why?
| | Surveys and Questionnaires | 9 | 2026 | 6055 | 0.110 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 32 | 0.110 |
Why?
| | Respiratory System | 1 | 2016 | 150 | 0.110 |
Why?
| | Dexmedetomidine | 1 | 2015 | 47 | 0.110 |
Why?
| | Spinal Fusion | 3 | 2020 | 261 | 0.110 |
Why?
| | Adiposity | 2 | 2022 | 532 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.110 |
Why?
| | Evoked Potentials, Motor | 2 | 2015 | 52 | 0.110 |
Why?
| | Whole Genome Sequencing | 2 | 2026 | 177 | 0.110 |
Why?
| | Respiratory Muscles | 1 | 2014 | 37 | 0.100 |
Why?
| | Sex Factors | 5 | 2025 | 2099 | 0.100 |
Why?
| | Evoked Potentials | 1 | 2015 | 131 | 0.100 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 955 | 0.100 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 186 | 0.100 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 79 | 0.100 |
Why?
| | Body Composition | 4 | 2021 | 690 | 0.100 |
Why?
| | Health Status | 2 | 2022 | 832 | 0.100 |
Why?
| | Machine Learning | 1 | 2019 | 586 | 0.100 |
Why?
| | Heart | 1 | 2017 | 626 | 0.100 |
Why?
| | Spine | 1 | 2015 | 181 | 0.100 |
Why?
| | Haplotypes | 2 | 2025 | 498 | 0.100 |
Why?
| | Up-Regulation | 1 | 2016 | 846 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 600 | 0.090 |
Why?
| | Brain | 1 | 2025 | 2934 | 0.090 |
Why?
| | Sex Distribution | 5 | 2014 | 386 | 0.090 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 243 | 0.090 |
Why?
| | Aorta | 1 | 2015 | 439 | 0.090 |
Why?
| | Colorado | 6 | 2021 | 4538 | 0.090 |
Why?
| | Incidence | 4 | 2024 | 2915 | 0.090 |
Why?
| | Prognosis | 5 | 2024 | 4310 | 0.090 |
Why?
| | Blood Vessels | 1 | 2013 | 167 | 0.090 |
Why?
| | Triglycerides | 2 | 2011 | 520 | 0.090 |
Why?
| | Time Factors | 7 | 2024 | 7107 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 582 | 0.090 |
Why?
| | Reference Values | 4 | 2023 | 798 | 0.080 |
Why?
| | Haptoglobins | 1 | 2011 | 71 | 0.080 |
Why?
| | Radiography | 4 | 2016 | 852 | 0.080 |
Why?
| | Genotype | 4 | 2024 | 1844 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1955 | 0.080 |
Why?
| | Occupational Exposure | 1 | 2014 | 355 | 0.080 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2023 | 75 | 0.080 |
Why?
| | Registries | 1 | 2019 | 2401 | 0.080 |
Why?
| | Electrodiagnosis | 1 | 2010 | 17 | 0.080 |
Why?
| | Adolescent | 6 | 2022 | 22479 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 427 | 0.080 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.080 |
Why?
| | Iliac Artery | 1 | 2010 | 55 | 0.080 |
Why?
| | Coma | 1 | 2009 | 38 | 0.080 |
Why?
| | Meningomyelocele | 1 | 2010 | 62 | 0.080 |
Why?
| | Patient Education as Topic | 2 | 2005 | 775 | 0.080 |
Why?
| | Hypertension | 5 | 2015 | 1269 | 0.070 |
Why?
| | Facial Nerve | 1 | 2009 | 39 | 0.070 |
Why?
| | Alcohol Drinking | 2 | 2009 | 836 | 0.070 |
Why?
| | Anesthesia, General | 2 | 2021 | 120 | 0.070 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 20 | 0.070 |
Why?
| | Uric Acid | 1 | 2010 | 167 | 0.070 |
Why?
| | Pediatric Obesity | 1 | 2017 | 637 | 0.070 |
Why?
| | Aortic Diseases | 1 | 2010 | 125 | 0.070 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 35 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 1795 | 0.070 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1995 | 0.070 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 49 | 0.070 |
Why?
| | Airway Remodeling | 2 | 2021 | 63 | 0.070 |
Why?
| | Odds Ratio | 4 | 2014 | 1082 | 0.070 |
Why?
| | Intraoperative Complications | 1 | 2010 | 157 | 0.070 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 39 | 0.070 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 103 | 0.070 |
Why?
| | Retrospective Studies | 8 | 2021 | 17247 | 0.070 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 24 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 104 | 0.070 |
Why?
| | Reproducibility of Results | 5 | 2017 | 3410 | 0.070 |
Why?
| | Neurosurgical Procedures | 1 | 2010 | 202 | 0.070 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.070 |
Why?
| | Kidney | 1 | 2016 | 1494 | 0.070 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 286 | 0.070 |
Why?
| | Coronary Angiography | 2 | 2014 | 328 | 0.070 |
Why?
| | Face | 1 | 2009 | 174 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.070 |
Why?
| | Spinal Cord | 1 | 2010 | 382 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 554 | 0.060 |
Why?
| | Life Style | 1 | 2009 | 483 | 0.060 |
Why?
| | Dietary Fats | 1 | 2009 | 308 | 0.060 |
Why?
| | Inflammation | 2 | 2021 | 2876 | 0.060 |
Why?
| | Heart Rate | 1 | 2010 | 855 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 80 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 19 | 0.060 |
Why?
| | Apolipoproteins C | 1 | 2006 | 3 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2010 | 424 | 0.060 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2026 | 103 | 0.060 |
Why?
| | Iceland | 1 | 2025 | 11 | 0.060 |
Why?
| | Mortality | 2 | 2019 | 378 | 0.060 |
Why?
| | Contraception | 1 | 2008 | 170 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2019 | 500 | 0.060 |
Why?
| | Organ Specificity | 1 | 2026 | 308 | 0.060 |
Why?
| | Child, Preschool | 4 | 2024 | 11835 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2025 | 6435 | 0.060 |
Why?
| | Internationality | 2 | 2017 | 156 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 442 | 0.060 |
Why?
| | Propensity Score | 2 | 2019 | 374 | 0.060 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 527 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2005 | 77 | 0.060 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2025 | 86 | 0.050 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2025 | 46 | 0.050 |
Why?
| | Abdominal Wall | 1 | 2004 | 28 | 0.050 |
Why?
| | Protein Interaction Maps | 1 | 2024 | 51 | 0.050 |
Why?
| | Drug Repositioning | 1 | 2024 | 39 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1703 | 0.050 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 11 | 0.050 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 517 | 0.050 |
Why?
| | Amygdala | 1 | 2025 | 199 | 0.050 |
Why?
| | Laryngeal Nerves | 1 | 2023 | 7 | 0.050 |
Why?
| | Laryngeal Muscles | 1 | 2023 | 10 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 442 | 0.050 |
Why?
| | HLA Antigens | 1 | 2025 | 238 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 360 | 0.050 |
Why?
| | Reflex | 1 | 2023 | 70 | 0.050 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 765 | 0.050 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 199 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 376 | 0.050 |
Why?
| | United Kingdom | 1 | 2024 | 336 | 0.050 |
Why?
| | Infant | 3 | 2025 | 10060 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 279 | 0.040 |
Why?
| | Antigens, CD | 1 | 2005 | 558 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 172 | 0.040 |
Why?
| | Blood Platelets | 1 | 2005 | 379 | 0.040 |
Why?
| | Insulin | 3 | 2022 | 2510 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 322 | 0.040 |
Why?
| | Muscles | 1 | 2022 | 330 | 0.040 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 172 | 0.040 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 46 | 0.040 |
Why?
| | Biological Variation, Population | 1 | 2021 | 20 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1371 | 0.040 |
Why?
| | Hepacivirus | 1 | 2023 | 242 | 0.040 |
Why?
| | Plethysmography | 1 | 2021 | 104 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 99 | 0.040 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 26 | 0.040 |
Why?
| | Reaction Time | 2 | 2015 | 431 | 0.040 |
Why?
| | Mice | 3 | 2026 | 18303 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 446 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2021 | 142 | 0.040 |
Why?
| | Diskectomy, Percutaneous | 1 | 2020 | 1 | 0.040 |
Why?
| | Animals | 4 | 2026 | 37952 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 419 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 106 | 0.040 |
Why?
| | Diskectomy | 1 | 2020 | 24 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1092 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 557 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 671 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 483 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 1002 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 7 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1300 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Hippocampus | 1 | 2025 | 969 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 571 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 231 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 45 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 89 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 40 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 967 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 11741 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 690 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 484 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 819 | 0.030 |
Why?
| | Lipids | 2 | 2017 | 706 | 0.030 |
Why?
| | Europe | 1 | 2019 | 416 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1043 | 0.030 |
Why?
| | Systems Biology | 1 | 2018 | 68 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2023 | 2524 | 0.030 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 26 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 483 | 0.030 |
Why?
| | Electric Impedance | 1 | 2017 | 108 | 0.030 |
Why?
| | Exercise | 1 | 2009 | 2191 | 0.030 |
Why?
| | Electroencephalography | 1 | 2021 | 561 | 0.030 |
Why?
| | Electrocardiography | 2 | 2010 | 664 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 101 | 0.030 |
Why?
| | Endoscopy | 1 | 2020 | 317 | 0.030 |
Why?
| | Total Lung Capacity | 1 | 2016 | 29 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 337 | 0.030 |
Why?
| | Bronchial Arteries | 1 | 2016 | 12 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1048 | 0.030 |
Why?
| | Michigan | 1 | 2017 | 134 | 0.030 |
Why?
| | Causality | 1 | 2017 | 126 | 0.030 |
Why?
| | RNA | 1 | 2023 | 910 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 968 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 329 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 283 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 492 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 42 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 591 | 0.030 |
Why?
| | Cough | 1 | 2016 | 123 | 0.030 |
Why?
| | Automation | 1 | 2015 | 104 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 69 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 332 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 276 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5582 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 617 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 236 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 775 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1262 | 0.030 |
Why?
| | Child | 3 | 2025 | 22670 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 506 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 220 | 0.020 |
Why?
| | Stroke | 1 | 2003 | 1270 | 0.020 |
Why?
| | Dyslipidemias | 1 | 2015 | 184 | 0.020 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 95 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 3892 | 0.020 |
Why?
| | Angiography | 1 | 2013 | 208 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3114 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1293 | 0.020 |
Why?
| | Vascular Stiffness | 1 | 2017 | 486 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 331 | 0.020 |
Why?
| | Exercise Test | 1 | 2014 | 626 | 0.020 |
Why?
| | Laminectomy | 1 | 2010 | 31 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 484 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5972 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 2057 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2010 | 30 | 0.020 |
Why?
| | Internal Fixators | 1 | 2010 | 32 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 122 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 26 | 0.020 |
Why?
| | Thoracic Vertebrae | 1 | 2010 | 81 | 0.020 |
Why?
| | Neural Tube Defects | 1 | 2010 | 67 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 661 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 23 | 0.020 |
Why?
| | Functional Laterality | 1 | 2010 | 240 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 101 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 143 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 356 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 133 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 450 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 3338 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 100 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 517 | 0.020 |
Why?
| | Scoliosis | 1 | 2010 | 221 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1845 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2010 | 2961 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 419 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 380 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 209 | 0.010 |
Why?
| | Self Care | 1 | 2009 | 388 | 0.010 |
Why?
| | Patient Selection | 1 | 2010 | 733 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 302 | 0.010 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 37 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 99 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 402 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 205 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2458 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2009 | 689 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 888 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1159 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1244 | 0.010 |
Why?
| | Risk | 1 | 2003 | 916 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2900 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 379 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1433 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1351 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1393 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|